Author(s):
Vishal T. Pawar, Shivraj P. Jadhav, Mayur S. Bhamare, Sunil K. Mahajan
Email(s):
vishalpawar64940@gmail.com
DOI:
10.52711/2231-5691.2026.00009 
Address:
Vishal T. Pawar1*, Shivraj P. Jadhav2, Mayur S. Bhamare3, Sunil K. Mahajan3
1Department of Industrial Pharmacy, SSS’s Divine College of Pharmacy, Satana, Nashik, Maharashtra, India.
2Department of Pharmaceutics, SSS’s Divine College of Pharmacy, Satana, Nashik, Maharashtra, India.
3Department of Pharmaceutical Quality Assurance, SSS’s Divine College of Pharmacy, Satana, Nashik, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2026
ABSTRACT:
The pharmaceutical industry operates within a highly regulated environment to ensure that medicines are safe, effective, and of high quality. Regulatory Affairs (RA) is a critical function that oversees compliance with national and international laws and guidelines throughout the drug development and marketing process. Regulatory professionals serve as the key link between pharmaceutical companies and health authorities, such as the US FDA, EMA, CDSCO, PMDA, and others, by preparing and submitting dossiers, obtaining product approvals, and maintaining post-approval compliance. This review article explores the multifaceted role of regulatory affairs in the pharmaceutical sector. It outlines how RA contributes at each stage of the product lifecycle from early-stage development and clinical trials to regulatory submissions, labeling, marketing authorization, and pharmacovigilance. The article also examines various regulatory pathways including New Drug Applications (NDA), Abbreviated NDAs (ANDA), and Biological License Applications (BLA), along with global initiatives such as the International Council for Harmonisation (ICH) and Common Technical Document (CTD/eCTD) formats that support harmonized submissions. In recent years, the regulatory landscape has undergone rapid changes due to the increasing complexity of drug molecules, the emergence of biologics and personalized medicine, and the integration of digital technologies in healthcare. Regulatory Affairs is adapting to these changes through enhanced digital tools, AI-driven documentation systems, and more collaborative regulatory frameworks. However, challenges persist, including regional regulatory differences, lengthy approval timelines, and evolving compliance standards. By providing a comprehensive overview of the current practices, challenges, and future directions, this review emphasizes the indispensable role of Regulatory Affairs in bringing safe and effective pharmaceutical products to market while ensuring patient safety and public health.
Cite this article:
Vishal T. Pawar, Shivraj P. Jadhav, Mayur S. Bhamare, Sunil K. Mahajan. Regulatory Affairs in Pharmaceutical Industry. Asian Journal of Pharmaceutical Research. 2026; 16(1):74-2. doi: 10.52711/2231-5691.2026.00009
Cite(Electronic):
Vishal T. Pawar, Shivraj P. Jadhav, Mayur S. Bhamare, Sunil K. Mahajan. Regulatory Affairs in Pharmaceutical Industry. Asian Journal of Pharmaceutical Research. 2026; 16(1):74-2. doi: 10.52711/2231-5691.2026.00009 Available on: https://asianjpr.com/AbstractView.aspx?PID=2026-16-1-9
12. REFERENCES:
1. Lale S, Kendre A, Gandhi M, Dani S. Role of drug regulatory affairs in Pharma Industry. World Journal of Pharmaceutical Research SJIF. 2015 Mar 27; 4(6):615-25.
2. Rägo L, Santoso B. Drug regulation: history, present and future. Drug benefits and risks: International textbook of clinical pharmacology. 2008 Aug 6; 2:65-77.
3. Tamboli TH, Mane SR, Bais SK. Navigating compliance: The integral role of regulatory affairs in pharmaceutical industry. Int J Pharm Herb Technol. 2024; 2:2447-60.
4. Gorja A, Reddy CD, Sucharitha K, Tanmai S. Insights of regulatory affairs in the pharmaceutical industry–A. World. 2024; 3(2).
5. Lykken S. We really need to talk: Adapting FDA processes to rapid change. Food & Drug LJ. 2013; 68:357.
6. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola PJ, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the rheumatic diseases. 2010 Feb 1; 69(2):325-31.
7. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Archives of internal medicine. 2005 Jun 27; 165(12):1363-9.
8. Zeukeng MJ, Seoane-Vazquez E, Bonnabry P. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs. European journal of clinical pharmacology. 2018 Jun; 74(6):811-8.
9. 9Wilkerson JR. Navigating similarities and differences in national and international accreditation standards: A proposed approach using US agency requirements. Quality Assurance in Education. 2017 Apr 3; 25(2):126-45.
10. Judd T. Post-market Surveillance (PMS) of Medical Devices: From a Clinical Engineering Perspective. InInspection of Medical Devices: For Regulatory Purposes 2023 Nov 27 (pp. 93-114). Cham: Springer Nature Switzerland.
11. Hirshorn J, Monk D. 26 The regulation of therapeutic products in Australia. The Textbook of Pharmaceutical Medicine. 2009:613.
12. Rahi S, Rana A. Role of ICH guidelines in registration of pharmaceutical products. Int J Drug Regul Aff. 2023; 7(4):-. doi:10.22270/ijdra.v7i4.365
13. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities. Washington (DC): National Academies Press; 2010. Chapter 2, The Structure and Phases of Clinical Trials.
14. U.S. Food and Drug Administration (FDA). Abbreviated New Drug Application (ANDA). Silver Spring, MD: FDA; 2025
15. Kesselheim AS, Tan YT, Avorn J. The FDA’s expedited approval programs: implications for patients and physicians. JAMA. 2015; 313(22):2241–2242. doi:10.1001/jama.2015.4855
16. Arora S, Arora S. Rare diseases and orphan drugs: challenges, regulatory movements and market strategy. Information booklet. 2014:1-22.
17. Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014; 22(2):83–94. doi:10.1016/j.jsps.2013.05.003
18. European Medicines Agency (EMA). Guideline on the structure and content of the clinical overview and clinical summary of the dossier. Amsterdam: EMA; 2016.
19. Mahaparale S, Desai B. Role and overview of drug regulatory affairs in pharmaceutical industry with implementation of CTD and ECTD. Sonali al World J Pharm Res [Internet]. 2018 Feb 7; 7.
20. Khanderao GJ, Kubde JA, Hatwar PR, Bakal RL, Karule VG. A review on role of drug regulatory affairs in pharma industry.
21. Thormeyer D. The eCTD in Europe—From the Regulatory Affairs' Perspective. Pharmazeutische Industrie (Pharmind). 2010; 72(1):57.
22. Cedeno-Serna J. Investigational new drug (IND) application. InTranslational Sports Medicine 2023 Jan 1 (pp. 419-424). Academic Press.
23. Ali J, Baboota S, editors. Regulatory affairs in the pharmaceutical industry. Academic Press; 2021 Nov 14.
24. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016; 47:20–33. doi:10.1016/j.jhealeco.2016.01.012
25. Kumar V, Yadav A, Goyal AK, Mishra N. Pharmaceutical manufacturing and quality control of drugs: an overview. J Appl Pharm Sci. 2012; 2(6):11–18. doi:10.7324/JAPS.2012.2613.
26. U.S. Food and Drug Administration (FDA). Abbreviated New Drug Application (ANDA). Silver Spring, MD: FDA; 2025.
27. Edwards IR, Aronson JK. The importance of safety monitoring standards in PSURs. Pharmacoepidemiol Drug Saf. 2015; 24(9):897–902. doi:10.1002/pds.3838
28. Mukonzo JK, et al. Expanding regulatory science: Regulatory complementarity and reliance. Clin Transl Sci. 2024; 17(3):468–479.
29. Reggi V. Medicines Regulatory Harmonization: International Collaboration as a Key to Improve Public Health. Med Regul Aff J. 2017; DOI:10.5301/maapoc.0000001.
30. Han Y, Ceross A, Bergmann JHM. Uncovering Regulatory Affairs Complexity in Medical Products: A Qualitative Assessment Utilizing Open Coding and Natural Language Processing (NLP). arXiv [Preprint]. 2023 Dec 30.
31. Thomson K, Nachlis H. Emergency use authorizations during the COVID-19 pandemic: lessons from hydroxychloroquine for vaccine authorization and approval. Jama. 2020 Oct 6; 324(13):1282-3.
32. Singh JA, Upshur RE. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. The Lancet Infectious Diseases. 2021 Apr 1; 21(4):e103-9.
33. Seimetz D, Heller K, Richter J. Approval of first CAR-Ts: have we solved all hurdles for ATMPs?. Cell Medicine. 2019 Jan 17; 11:2155179018822781.
34. Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications... J Pharm Policy Pract. 2022; 15:6.
35. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency. AAPS PharmSciTech. 2017; 18(2):489–497.